DIA会员及用户请点击登录

登录

忘记用户 ID? or 忘记密码?

Not a Member?

创建账户并加入。

Bethesda North Marriott Hotel and Conference Center

2019 年 04 月 23 日 7:00 上午 - 2019 年 04 月 25 日 5:00 下午

5701 Marinelli Road, , North Bethesda, MD 20852 , USA

CMC Workshop

Explore how to utilize effective CMC strategies and execution and how it can help to reduce regulatory burden, enable shorter review timelines, and support post-approval maintenance.

Session 8 Track A: QbD Incorporation in Large Molecule Development and Regulatory Filings

Session Chair(s)

Stephane  Avella

Stephane Avella

Director, Global Regulatory Affairs, CMC Biologics

Merck, United States

Quality by Design (QbD) is no longer a regulatory initiative but an industry initiative supported by regulators. QbD approach can be applied throughout process development to enhance process and product understanding. QbD tools and principles can be leveraged to develop an effective integrated control strategy. This session will focus on practical approaches to accelerated QbD implementation and provide practical recommendations for realistic implementation of QbD elements.

Learning Objective : At the conclusion of this session, participants should be able to:
  • Understand QbD principles and tools
  • Understand how these tools can be applied throughout process development to enhance process and product understanding
  • Understand how a control strategy can be developed leveraging the QbD tools and principles

Speaker(s)

Hong  Li

Quality by Design Applied in Large Molecule CMC Development

Hong Li

Merck Co, INC., United States

Director

Arne  Staby, PhD

QbD Case Stories – Process Understanding for Biotech Products

Arne Staby, PhD

Novo Nordisk, Denmark

Scientific VP

获得信息并保持参与

不要错失任何机会——请加入我们的邮件列表,了解DIA的观点和事件。